Analysis of effectiveness criteria in pharmacoeconomic studies of hypoglycemic drugs proposed for inclusion into the essential drug list in 2014-2016 in Russia

by A. A. Mosikyan, A. A. Kurylev, A. S. Kolbin
Published 2018-05-01

Biomarkers associated with atherogenesis: current status and promising areas

by M. A. Magruk, A. A. Mosikyan, A. Yu. Babenko
Published 2019-12-01

Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and...

by A S Kolbin, A A Mosikyan, Y E Balykina, M A Proskurin
Published 2018-03-01

Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, tax...

by A S Kolbin, A A Mosikyan, A A Kurilev, Yu E Balykina, M A Proskurin
Published 2017-01-01

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2

by A. S. Kolbin, A. A. Mosikyan, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, W. Zhao
Published 2018-05-01

Budget impact analysis: principles of good practice. Report of the ISPOR Working Group on Good Practices for Budget Impact Analysis II, 2012

by Sean D. Sullivan, Josephine A. Mauskopf, Federico Augustovski, J. Jaime Caro, Karen M. Lee, Mark Minchin, Ewa Orlewska, Pete Penna, Jose-Manuel Rodriguez Barrios, Wen-Yi Shau, T. L. Galankin, A. A. Mosikyan, A. S. Kolbin
Published 2018-05-01